Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water is a solvent and diluent for parenteral administration; it provides hydration and maintains osmotic balance. It has no pharmacological activity.
The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.
As a diluent for reconstitution of medications,As a vehicle for intravenous administration of compatible drug additives,For hydration in patients requiring fluid replacement
FDA-approved for continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) in patients with end-stage renal disease (ESRD),Off-label uses include acute kidney injury (AKI) requiring dialysis in select settings
Intravenous administration; dose determined by clinical requirements for hydration, drug dilution, or vehicle for parenteral medications. Typical adult maintenance: 30 m L/kg/day, adjusted for electrolyte and fluid status.
Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.
Approximately 30-45 minutes; rapid redistribution due to constant renal clearance; clinically, water half-life is not typically measured since it is a vehicle
Calcium: terminal half-life 4-6 hours in patients with normal renal function; magnesium: terminal half-life 3-5 hours. Prolonged in renal impairment.
Water is not metabolized; it is distributed throughout body fluids and excreted primarily by the kidneys.
The solution components (bicarbonate, lactate, dextrose, electrolytes) are not metabolized by the liver; bicarbonate and lactate are buffer precursors converted via endogenous pathways; dextrose is absorbed and metabolized systemically; electrolytes are regulated by renal and non-renal mechanisms.
Renal: >99% as free water; biliary/fecal: negligible
Primarily renal excretion; ~70% of calcium dose and ~60% of magnesium dose excreted unchanged in urine. Fecal elimination accounts for ~20% and ~30%, respectively. Biliary excretion is minimal.
0% (water does not bind to plasma proteins)
Calcium: ~40-50% bound to albumin; magnesium: ~25-30% bound to albumin. Binding decreases in hypoalbuminemia.
0.55-0.7 L/kg (total body water); clinically, water distributes throughout total body water
Calcium: 0.25-0.4 L/kg; magnesium: 0.5-0.7 L/kg. Indicates distribution into extracellular fluid and bone (calcium) or intracellular and bone (magnesium).
Intravenous: 100%; subcutaneous: ~100% (complete absorption); intramuscular: ~100%
Intravenous: 100%. Intraperitoneal: ~70-80% (dependent on dwell time and concentration). Oral: ~30-40% for calcium and ~40-60% for magnesium (varies with formulation and GI factors).
No specific GFR-based dose adjustment; monitor fluid balance and avoid fluid overload in renal impairment. In oliguric or anuric patients (GFR <10 m L/min), reduce volume to match insensible losses plus urine output.
For GFR 30-60 m L/min: reduce amino acid dose to 0.8 g/kg/day. For GFR <30 m L/min: reduce to 0.6 g/kg/day. Lipids may require adjustment based on triglyceride levels. Avoid in severe renal failure unless on dialysis.
No specific Child-Pugh based modification; use with caution in ascites or edema due to risk of fluid overload.
Child-Pugh A: no adjustment. Child-Pugh B: reduce amino acids to 1.0 g/kg/day. Child-Pugh C: avoid use or reduce to 0.5 g/kg/day with close monitoring for encephalopathy. Lipids may be given at standard doses but monitor triglycerides.
Weight-based: Neonates and infants: 60-100 m L/kg/day for maintenance; adjust for dehydration or ongoing losses. Administer via intravenous route.
Neonates and infants: amino acids 2.0-3.0 g/kg/day, lipids 1.0-3.0 g/kg/day. Children 1-10 years: amino acids 1.5-2.5 g/kg/day, lipids 1.0-2.0 g/kg/day. Administer via continuous infusion over 24 hours. Monitor serum triglycerides, bilirubin, and liver function.
Use lower end of dosing range due to decreased renal function and comorbidities; monitor for fluid overload and electrolyte disturbances. Typical starting dose: 20-30 m L/kg/day intravenously.
Use caution; start at low end of adult dosing (amino acids 1.2 g/kg/day, lipids 1.0 g/kg/day). Monitor renal function (creatinine clearance) and fluid status due to increased risk of fluid overload. No specific dose adjustments except based on renal function.
None.
Not for intravenous use. Peritoneal dialysis should be performed under strict aseptic technique to prevent peritonitis. Use only in patients with intact peritoneal membrane and no contraindications to peritoneal dialysis.
Use only if solution is clear and container is intact,Do not use for intravenous injections that require isotonic solutions unless additives are used to achieve isotonicity,Risk of hemolysis if administered as a large volume hypotonic solution,Monitor for fluid overload in patients with renal impairment or cardiac disease
Monitor serum electrolytes, glucose, and acid-base status frequently. Risk of hyperglycemia, hypernatremia, hypokalemia, hypocalcemia, and metabolic alkalosis. Peritonitis and catheter-related infections are major complications. Avoid in patients with severe lactic acidosis or hypokalemia. Use caution in patients with glucose intolerance or liver disease.
Known hypersensitivity to any component,Use as a large volume intravenous infusion without appropriate additives to achieve isotonicity
Absolute: Hypersensitivity to any component, pre-existing severe metabolic alkalosis, documented non-functioning peritoneal membrane, or conditions compromising peritoneal integrity (e.g., extensive adhesions, diaphragmatic defects). Relative: Uncontrolled hyperglycemia, severe hypokalemia, or recent abdominal surgery.
No known food interactions. Patients on a sodium-restricted diet should be aware that this product contains no sodium.
No specific food interactions. However, patients should maintain a diet appropriate for chronic kidney disease on peritoneal dialysis, including controlled intake of potassium, phosphorus, and fluids as directed by their healthcare provider.
Sterile Water for Injection is a parenteral fluid devoid of pharmacologic activity. There is no known teratogenic risk across all trimesters; water is an essential nutrient with no expected fetal harm when administered appropriately.
Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.
Compatible with breastfeeding; water distributes into breast milk without known adverse effects. No M/P ratio applicable as it is a non-medicinal vehicle.
Excreted into breast milk in low amounts; M/P ratio not established; compatible with breastfeeding with monitoring of infant electrolytes.
No dose adjustment needed; water clearance and distribution remain unchanged in pregnancy.
Increased plasma volume in pregnancy may require dose adjustments; monitor serum potassium and calcium; hemofiltration dose may need increased frequency or volume.
Sterile water for injection is not intended for direct intravenous administration; it is used for reconstitution of medications or as a diluent. If given intravenously without proper tonicity adjustments, it can cause hemolysis, hyponatremia, and cerebral edema.
PHOXILLUM BK 4/2.5 is a peritoneal dialysis solution containing 4% icodextrin and 2.5% amino acids. It is used for one exchange per day in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Avoid use in patients with known hypersensitivity to icodextrin or amino acids. Monitor serum osmolality and glucose levels, as icodextrin may interfere with glucose oxidase-based glucometers, leading to falsely elevated readings. Use with caution in patients with liver disease due to potential amino acid accumulation.
This product is used to mix with other medications before they are given as an injection or infusion.,Do not inject this water directly into a vein as it can cause serious side effects.,Tell your healthcare provider if you have any allergies or if you are on a sodium-restricted diet.
Use only one bag per day, typically for the long dwell (overnight).,Do not use if the solution is cloudy or the bag is damaged.,Store at room temperature, away from direct sunlight.,Monitor for signs of infection like redness, swelling, or drainage at the catheter site.,Report any unusual abdominal pain or cloudy effluent immediately.,If using a glucose meter, ensure it is not affected by icodextrin; consider using a glucose dehydrogenase-based meter.,Maintain a balanced diet as amino acids may affect protein intake needs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER FOR INJECTION IN PLASTIC CONTAINER vs PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is a Irrigation Solution that works by Water is a solvent and diluent for parenteral administration; it provides hydration and maintains osmotic balance. It has no pharmacological activity.. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is a Irrigation Solution that works by The drug is a bicarbonate-based peritoneal dialysis solution that buffers metabolic acidosis, removes uremic toxins, and corrects electrolyte imbalances via diffusion and ultrafiltration across the peritoneal membrane. It does not have a traditional receptor-mediated mechanism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER FOR INJECTION IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is: Intravenous administration; dose determined by clinical requirements for hydration, drug dilution, or vehicle for parenteral medications. Typical adult maintenance: 30 m L/kg/day, adjusted for electrolyte and fluid status.. The standard adult dose of PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is: Intravenous infusion only. Each 1000 m L bag contains 4 g of amino acids and 2.5 g of lipids. Typical adult dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 37.5-50 m L/kg/day) and 1.0-1.5 g/kg/day of lipids. Administer at a rate not to exceed 0.11 g/kg/hour of amino acids and 0.15 g/kg/hour of lipids. For a 70 kg patient, this equals approximately 2.6-3.5 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER FOR INJECTION IN PLASTIC CONTAINER and PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is classified as Category C. Sterile Water for Injection is a parenteral fluid devoid of pharmacologic activity. There is no known teratogenic risk across all trimesters; water is an essential nutrient with no. PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER is classified as Category C. Limited data; no evidence of teratogenicity in animal studies; avoid if possible in first trimester due to theoretical risks of uremic toxin accumulation.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.